Home
|
Help
|
Contact
Sign in
WPRIM Management System>
DCMS
>
Chinese Journal of Urology
>
>
43
>
7
Volume:
43
Issue:
7
1. Progress of prostate cancer research at the 2022 American Urological Association annual meeting
Page:481—483
2. Clinical analysis of prostate targeted biopsy guided by multiparametric magnetic resonance imaging and 68Ga-PSMA PET/CT image fusion
Page:484—489
3. The preliminary study about feasibility and accuracy of the frozen section during targeted prostate biopsy
Page:490—494
4. Clinical value of 68Ga-PSMA PET/CT in outpatient screening of prostate cancer
Page:495—499
5. Efficacy of 68Ga-PSMA PET/CT in evaluating lymph node metastasis of prostate cancer
Page:500—504
6. Feasibility of radical prostatectomy without biopsy for patients with highly suspected localized prostate cancer diagnosed by mpMRI and 68Ga-PSMA PET/CT
Page:505—511
7. Analysis and interpretation of genetic testing results from 249 Chinese high to very-high risk non-metastatic prostate cancer patients
Page:512—517
8. Clinical factors of positive surgical margin after robot-assisted laparoscopic radical prostatectomy in patients with high-risk prostate cancer
Page:518—522
9. Influence of prostate cancer seminal vesicle invasion imaging classification on positive surgical margin after laparoscopic radical prostatectomy
Page:523—528
10. Study of gonadotropin-releasing hormone antagonist in management of hormonal sensitive prostate cancer
Page:529—534
11. Efficacy and safety of radium-223 in 48 patients with bone metastatic castration resistant prostate cancer
Page:535—539
12. Efficacy and safety of radium-223 in the treatment of metastatic castration resistant prostate cancer
Page:540—544
13. Therapeutic regimen with darolutamide for metastatic castration resistant prostate cancer: a case report
Page:545—547
14. Research progress of nano-medical materials in the diagnosis and treatment of prostate cancer
Page:548—551
15. Research progress of detection of lymph node metastases by 68Ga-PSMA PET in prostate cancer patients
Page:552—554
16. Adjuvant or salvage radiotherapy in patients with adverse pathological features after radical prostatectomy
Page:555—558